Navigation Links
Perrigo Reports Record Sales and Earnings for Third Quarter Fiscal 2008
Date:5/6/2008

372,526 282,045 246,582

Inventories 356,906 295,114 310,272

Current deferred income taxes 37,716 41,400 39,122

Income taxes refundable 4,684 - -

Assets held for sale 2,746 2,746 -

Prepaid expenses and other current

assets 16,146 18,340 23,833

Total current assets 855,851 719,060 712,902

Property and equipment 708,297 664,096 641,343

Less accumulated depreciation 372,618 333,024 320,672

335,679 331,072 320,671

Restricted cash 400,000 422,000 422,000

Goodwill 264,913 196,218 189,450

Other intangible assets 231,033 159,977 159,427

Non-current deferred income taxes 51,033 54,908 42,624

Other non-current assets 58,876 41,919 43,487

$2,197,385 $1,925,154 $1,890,561

Liabilities and Shareholders' Equity

Current liabilities

Accounts payable $229,744 $164,318 $158,499

Notes payable 10,169 11,776 3,763

Payroll and related taxes 54,849 46,226 43,590

Accrued customer programs 45,773 48,218 40,494

Accrued liabilities 39,039 47,333 48,135

Accrued income taxes - 29,460 16,210

Current deferred income taxes 18,864 17,125 13,886

Current portion of long-term debt 17,598 15,381 14,91
'/>"/>

SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Perrigo Company Announces Quarterly Dividend
2. Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum
3. Perrigo Company Will Release Third Quarter Fiscal 2008 Results on May 6, 2008
4. Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack
5. Perrigo Company to Present at the 12th Annual Sidoti Emerging Growth Institutional Investor Forum
6. Perrigo Company Announces Launch of Clobetasol Propionate Foam
7. Perrigo Company Receives Final Approval on Clobetasol Propionate Foam
8. Perrigo Company to Market Over-the-Counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets
9. Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets
10. Perrigo Company Announces Final FDA Approval for OTC Famotidine Complete Chewable Tablets
11. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... MI (PRWEB) October 22, 2014 ... Schools of Allied Health Professions (ASAHP) Conference on October ... and CEO will participate in a panel discussion on ... Practice. , Isabel Healthcare provides a diagnostic decision support ... improving the diagnosis skills of students and clinical learners. ...
(Date:10/22/2014)... 22, 2014 The Louis ... is dedicated to distribute health information technology innovation ... worldwide announced the development of six key guiding ... when receiving healthcare. These are an expansion of ... “providing care that is respectful of and responsive ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
(Date:10/22/2014)... MA (PRWEB) October 22, 2014 ... new solutions for the treatment of bacterial infections, microbial ... Sinskey has joined its board of directors. , ... and Engineering Systems at The Massachusetts Institute of Technology, ... MIT faculty since 1968. Dr. Sinskey also holds positions ...
(Date:10/22/2014)... By Maureen Salamon ... -- A crucial part of conventional in vitro fertilization (IVF) ... can instead take place in a device inside the vagina, ... Colombia contend that the device, called an INVOcell, might sharply ... could also make the technology more accessible to those who ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... Online Resource for Sharing Product, Educational Expertise,with ... B. Braun Medical Inc. (B.,Braun) has launched ... services,and educational and editorial information for ambulatory ... ), The new online resource, ...
... RALEIGH, N.C., Oct. 30 TeleHealth Services, Inc., ... healthcare,market, has named Matthew K. Barker to the ... will include strategic market planning,market research and analysis., ... Mr. Barker,to direct its marketing efforts for its ...
... Scheduled for Monday, November 3, 2008, ALEXANDRIA, Va., ... League (TSCL) filed an amicus brief in support of ... right to,damages for the amputation of her gangrenous arm ... Wyeth, with the wholehearted backing of the Food ...
... Oct. 30 Arno Therapeutics,Inc. (OTC Bulletin Board: ... today announced the appointment,of William F. Hamilton, Ph.D. ... of,the audit committee. Dr. Hamilton has over 40 ... with particular expertise in the areas of,technology strategy ...
... depression based on financial woes, SAN DIEGO, Oct. ... at the San Diego Convention Center today for the,2008 ... economic,crisis causing new waves of anxiety disorders to ripple ... Sunday. More than 100 sessions,and symposia are scheduled throughout ...
... of Yale University,s,Prevention Research Center Links KIND Fruit + Nut ... DERBY, Conn., Oct.30 Snacking -- at least on the ... to a recently,completed pilot study at The Yale-Griffin Prevention Research ... Fruit & Nut Delight,Bars per day for eight weeks along ...
Cached Medicine News:Health News:B. Braun Medical Inc. Launches Ambulatory Surgical Center Website 2Health News:TeleHealth Names Matthew K. Barker to New Director of Marketing Position 2Health News:The Senior Citizens League's Comments on U.S. Supreme Court Case Wyeth v. Levine 2Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 2Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 3Health News:Psychiatric Congress Opens Amid Growing Climate of Economy-Driven Anxieties 2Health News:Psychiatric Congress Opens Amid Growing Climate of Economy-Driven Anxieties 3Health News:Daily Snack Bars May Facilitate Weight Loss 2Health News:Daily Snack Bars May Facilitate Weight Loss 3Health News:Daily Snack Bars May Facilitate Weight Loss 4
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
(Date:10/22/2014)... 22, 2014  Regulus Therapeutics Inc. (NASDAQ: ... leading the discovery and development of innovative ... has demonstrated human proof-of-concept with a microRNA ... RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ... virus infection ("HCV").  Interim results from the ...
(Date:10/20/2014)... octubre de 2014  PneumRx, Inc. ( www.pneumrx.com ... pulmonología intervencional, anunció hoy la conclusión de la ... antes de lo programado. El Estudio Clínico RENEW es ... investigación (IDE) aprobada por la FDA (Administración de ... de reducción de volumen pulmonar PneumRx RePneu, un ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... 17 The United States, fifth hand transplant ... to Massena, New York this week after a ... Kleinert Kutz and University of Louisville ... hand surgeons performed the Hondusky,s hand transplant at ...
... as international hub for collaborative research, biotech start-upsDETROIT, ... University research and technology park, will soon ... lab in Michigan. The Wayne County Stem Cell ... Executive Robert Ficano, who publicly announced Wayne County,s ...
Cached Medicine Technology:Fifth U.S. Hand Transplant Patient Heads Home to NY 2Fifth U.S. Hand Transplant Patient Heads Home to NY 3Wayne County Partners With TechTown to Launch Global Stem Cell 'Innovation and Commercialization Lab' 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: